ReviewJournal of neural transmission (Vienna, Austria : 1996)2016
Psychosis in Parkinson's disease: identification, prevention and treatment.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Diagnostics and treatment of impulse control disorders, psychosis and delirium: systemic review-based recommendations - guideline "Parkinson's disease" of the German Society of Neurology.Journal of neurology · 2024Guideline
- Visual hallucinations in Parkinson's disease are associated with deficits in social perception.Journal of Parkinson's disease · 2025Article
- Approaches for treating neuropsychiatric symptoms in Parkinson's disease: a narrative review.Therapeutic advances in neurological disorders · 2025Review
- Clinical characteristics and treatment of psychosis in Parkinson's disease: A narrative review.Journal of the Chinese Medical Association : JCMA · 2024Review
- Electromyographic Characteristics of Postactivation Effect in Dopamine-Dependent Spectrum Models Observed in Parkinson's Disease and Schizophrenia.Biomedicines · 2024Article
- Parkinson's disease updates: Addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment.Annals of medicine and surgery (2012) · 2023Review
- Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel.Neurology and therapy · 2022Article
- Review
- Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries.Neurology and therapy · 2022Article
- Mapping brain structural differences and neuroreceptor correlates in Parkinson's disease visual hallucinations.Nature communications · 2022Article
- QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.Neuropsychiatric disease and treatment · 2021Review
- Increased risk of falls and fractures in patients with psychosis and Parkinson disease.PloS one · 2021Article
- A Preliminary Investigation of the Views of People With Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: An Online Survey.Frontiers in psychiatry · 2020Article
- Features ofJournal of neurology, neurosurgery, and psychiatry · 2018Observational
- Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition.Parkinson's disease · 2017Review
- Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson's patients.European journal of clinical pharmacology · 2016Article
- Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.The Clinical neuropsychologist · 2016Review
- Nonlinear parameters of surface EMG in schizophrenia patients depend on kind of antipsychotic therapy.Frontiers in physiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychosis in Parkinson's disease (PD) is a frequent condition affecting >20 % of all PD patients. It is characterized by vivid dreams, nightmares, illusions, delusions and mostly visual hallucinations. Typically psychosis occurs in the late stage of PD, affecting up to 70 % of the patients following a disease duration of 20 years or more, and can severely interfere with the care of the patients, especially if the patients develop delusions. Psychosis is the principal cause of admission to a nursing home for PD patients. Hence, preemptive identification of risk factors, and avoidance and elimination of triggers are most important measures against psychosis in PD patients. Secondarily, pharmaceutical measures are being undertaken successively, including simplification of medication regimes, discontinuation of non-essential CNS-active drugs, ordered reduction of antiparkinsonian drugs, addition of cholesterinase inhibitors in cognitively impaired patients, and finally addition of antipsychotic medication with limited parkinsonian side effects. As psychosis in PD is a frequent and important problem, we set out to write a state-of-the-art guideline for its identification and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.